TY  - JOUR

T1  - Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/91088

UR  - http://dx.doi.org/10.1007/s40273-015-0334-3

PY  - 2016/03/01

AU  - Essat M

AU  - Tappenden P

AU  - Ren S

AU  - Bessey A

AU  - Archer R

AU  - Wong R

AU  - Lobo A

AU  - Hoque S

ED  - 

DO  - DOI: 10.1007/s40273-015-0334-3

PB  - Springer Verlag

Y2  - 2025/10/31

ER  -